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Abstract
As the number of individuals suffering from tissue loss and end-stage organ failure continues to
grow, researchers are turning to tissue engineering to provide better methods of treatment. The
field, however, still faces many technical challenges that are limiting its applications. One
challenge faced in engineering more complex tissues and organs is the need for inherent
microvasculature to supply the tissue with nutrients and oxygen. Researchers at The Charles
Stark Draper Laboratory have developed a method for engineering microvascular networks in
vitro using various microfabrication techniques. This paper discusses the current state of the
research and technical challenges to overcome before commercializing the technology. The
feasibility of using the networks in the nearer term application of treating chronic wounds will
also be assessed, and a potential business strategy will be laid out.
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1 Introduction
In the past few decades, the field of tissue engineering has emerged to address the
growing issue of tissue loss and organ failure among individuals. Currently, more than half of
U.S. health care expenditures, or over $600 billion, are spent treating these conditions.1
Transplants, autografts, and prostheses have been used with some success thus far, but these
methods are accompanied by problems of limited supply and lack of long term biocompatibility.
While tissue engineering seeks to provide a superior alternative to current methods of treatment,
many challenges must be overcome before its applications can be made widely available for
clinical use. One major challenge faced in engineering complex organs is the necessity of
microvasculature to deliver nutrients and oxygen and remove waste. Researchers at The Charles
Stark Draper Laboratory are attempting to address this issue by fabricating three dimensional
microfluidic networks to serve as in vitro engineered microvasculature in tissue engineering
applications. This paper serves to assess the current state of the technology and the feasibility of
its nearer term application in the treatment of chronic wounds.
2 Background
2.1 Tissue Engineering
The field of tissue engineering draws on knowledge from engineering and science
disciplines to accomplish two main purposes: to achieve a better understanding of tissue
structure-function relationships and to use this understanding to develop biological substitutes to
regenerate and repair tissue.2 As research continues, new approaches to restoring tissue loss and
organ failure will be introduced. Current approaches such as transplants, autografts, and
prostheses have saved many lives and improved the quality of life for many others. However,
these approaches are far from sufficient. With transplants, the demand far exceeds the supply.
In 2002, there were 79,512 patients waiting for transplants in the U.S. alone. Less than a third
received organs, and over 6,000 died waiting on the list.3 Currently, there are 96,957 individuals
awaiting transplants. With only 9,218 transplants performed in the first four months of this year,
there is an obvious need for additional therapies.4 Even after receiving a transplant, there is
always the concern of organ rejection. Other conditions such as burns or bone and vascular
injuries may be treated with autografts. By using tissue grafts from the patients themselves,
concerns of rejection are eliminated; however, availability is even more limited. In some cases,
the physical function of injured organs can be maintained through the use of prostheses;
examples include artificial hips and pacemakers. While prostheses are considered biocompatible,
they are still accompanied by long-term complications.5 Tissue engineering shows great
potential for serving as an approach that addresses all of these problems.
The goal of developing biological substitutes has been approached through a variety of in
vivo and in vitro methods. Several strategies deal only with the isolation and expansion of cell
cultures and cell substitutes. Others focus on the identification, purification, and production of
biomolecules that induce tissue regeneration. Lastly, much research has concentrated on the
development of matrices to aid in the regeneration of tissue.6 These matrices, designed to
possess properties similar to those of the tissue to be regenerated, also often incorporate cells
and/or biomolecules. They can be implanted immediately at the site of injury or allowed to
synthesize tissue in vitro prior to implantation.5
2.1.1 Tissue Engineering of Skin
2.1.1.1 Cutaneous Wounds
The skin (Figure 1) consists of two layers, the epidermis and dermis, which are separated
by a basement membrane. Although it is only approximately 100 pm thick, the epidermis serves
as the body's primary protective barrier against infection and fluid loss. The dermis is a thicker
layer of vascular connective tissue that contains skin appendages such as sweat glands, hair
follicles, and sebaceous glands. It provides mechanical and metabolic support for the thinner,
avascular epidermis.
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Figure 1. Anatomy of skin7
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When only the epidermis and basement membrane sustain injury, the body is able to
spontaneously regenerate the lost tissue. Wounds that extend into the dermis, on the other hand,
are healed through a repair process. The tissue resulting from this process differs structurally
from that of the original tissue.5 Deeper wounds are described as partial or full thickness wounds
when a portion or all of the dermis is injured in addition to the epidermis. Partial thickness
wounds can be further categorized as superficial or deep to describe the degree of damage to the
dermis more precisely.8
2.1.1.2 Physiology of Wound Healing
The repair process (Figure 2) of a typical wound consists of three phases: inflammation,
proliferation, and remodeling. Two main responses occur during the inflammation phase: a
vasomotor-vasopermeability response and leukocyte infiltration. Immediately after injury,
hemostasis is reestablished through vasoconstriction and the formation of a fibrin clot via platelet
adhesion. Subsequent vasodilation and increased capillary permeability allow protein-rich serum
and cell populations to infiltrate the wound. 9 These cells are attracted by the chemical signals
released as the wound healing process is initiated. Neutrophils begin the process of cleansing the
wound and preventing infection. Monocytes also migrate to the wound and develop into
macrophages. These cells continue to cleanse the wound through phagocytosis and also release
growth factors necessary for the continuation of the repair process. 1'
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Figure 2. Acute vs. impaired chronic wound healing. Reprinted by permission from Macmillan Publishers
Ltd: Journal of Investigative Dermatology Vol. 127, 1018-1029, copyright 2007.12
TGF - transforming growth factor; FGF - fibroblast growth factor; VEGF - vascular endothelial growth
factor; PDGF - platelet-derived growth factor; IGF - insulin-like growth factor; KGF - keratinocyte growth
factor; GT - granulation tissue
The proliferation phase begins two to three days after injury and is dominated by
fibroblast activity. Fibroblasts proliferate, migrate to the wound, and begin synthesizing
extracellular matrix (ECM) components, including collagen and glycosaminoglycans (GAGs), to
replace lost connective tissue. Angiogenesis also occurs during this phase to support the
metabolic needs of the fibroblasts. 9 As a result, the newly synthesized tissue is highly
vascularized, giving it a granular appearance and thus its name - granulation tissue. 10 If
angiogenesis fails to occur, fibroblast migration is halted, and wound healing is inhibited. 9
Reepithelialization begins hours after injury with the migration of keratinocytes from skin
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appendages and wound edges and continues throughout the proliferation phase. In the second
week after injury, myofibroblasts also begin compacting connective tissue and contracting the
wound to aid in wound closure.10
The final phase of wound healing begins after homeostasis between collagen synthesis
and degradation has been achieved. This occurs approximately three weeks after the wound is
created, but remodeling can continue for up to two years. As remodeling occurs, many of the
blood vessels and fibroblasts in the newly synthesized connective tissue undergo apoptosis,
transforming the granulation tissue into a scar. Collagen fibers are also reorganized to strengthen
the new tissue.' 0 The wound strength gradually increases from approximately 20% (at three
weeks after injury) until it plateaus at 70-80% of the strength of undamaged tissue.9'10
The final morphology of the repaired skin differs from normal skin in several ways.
Normal dermal tissue consists of randomly aligned collagen fibers, and the dermo-epidermal
junction contains rete ridges. In scar tissue produced through repair, collagen fibers are mainly
aligned in the plane of the epidermis, and the dermo-epidermal junction lacks the characteristic
rete ridges. Additional differences include the composition of the connective tissue and lack of
skin appendages that were damaged during injury.3
In some cases, the wound healing process does not complete properly, resulting in a
chronic wound (Figure 2). Chronic wounds are characterized by a lack of epidermal migration
and granulation tissue growth; this often results from difficulty in moving past the inflammation
phase."1, 12 A variety of issues can lead to the inhibition of healing. Vascular problems that may
contribute to the problem range from arterial insufficiency to venous hypertension to the failure
of angiogenesis at the wound site. Without functioning vasculature to maintain metabolic
activities, fibroblasts are unable to continue migrating and synthesizing new tissue. In other
cases, sufficient amounts of growth factors may be lacking due either to undersecretion or rapid
metabolism. Other factors including infection and edema, the accumulation of fluid in tissues,
may also slow healing.9 Some chronic wounds will eventually heal with increased amounts of
granulation tissue and fibrosis, which lead to significant scarring and reduction of functionality. 9
2.1.1.3 Current State ofResearch
Research regarding the tissue engineering of skin has resulted in the development of
many commercialized skin substitutes for use in cutaneous wound healing. Scientists are now
capable of isolating and expanding keratinocyte cultures by 10,000 fold in 2-3 weeks. This has
allowed for the development of autologous and allogeneic epidermal replacements using cultures
from patients and neonatal foreskin, respectively. 12,13 Two main types of dermal substitutes have
also been developed. Cadaveric allografts have been treated to remove immunogenic elements
such as cells and in some cases, the epidermis. Other dermal substitutes have been prepared by
constructing scaffolds from ECM components. In some cases, these matrices are subsequently
seeded with allogeneic fibroblasts. Bilayered skin substitutes are the most recent advances to be
commercialized. These substitutes provide both an epidermal component with keratinocytes and
a dermal component with fibroblasts.' 2 While both skin components are supplied, they are
limited in thickness and do not always take well. This is due to the fact that they lack
vascularization to supply nutrients to the cells within the scaffolds. The cells must rely on
imbibition, or the diffusion of nutrients, until neovascularization occurs.14
2.1.2 Tissue Engineering of Microvasculature
While thinner and simpler tissues have been successfully engineered, the challenge of
engineering vascularized tissue has prevented the engineering of thicker and more complex
tissues. While the former is capable of relying initially on diffusion for oxygen and nutrients, the
latter cannot.14 An inherent vasculature would enable the engineering of tissues with greater
metabolic needs and thicknesses greater than the 100-200 gtm nutrient diffusion limit.3
To date, success in engineering vasculature has been primarily confined to individual,
large diameter (> 5 mm) blood vessels. Bypass grafts have been constructed using Dacron and
expanded polytetrafluoroethylene (ePTFE). These materials, however, have proven insufficient
for smaller diameter blood vessel substitutes due to their thrombogenicity. 5 Clotting and
scarring of the blood vessels often leads to stricturing or even complete occlusion. To counteract
this effect, many devices are coated with anti-thrombogenic coatings, such as heparin-based
coatings. Researchers have also begun conducting studies on lining materials with endothelial
cells to prevent thrombosis.
Although researchers are currently investigating a wide range of methods for engineering
blood vessels with a high patency, the gold standard for microvascular grafts (internal diameter <
1 mm) is still the autologous vein graft. Autografts, however, cannot be used to provide
microvasculature for tissue-engineered organs due to the fact that a complete and intact capillary
bed cannot be dissected out. 14 Researchers have thus turned to two possibilities for providing
regenerated or engineered tissue with microvasculature: therapeutic angiogenesis and the
inosculation of pre-vascularized tissue constructs.
Therapeutic angiogenesis, also referred to as angioinduction, attempts to stimulate the
formation of new blood vessels from a host's existing vasculature through the delivery of
angiogenic molecules. These molecules are typically growth factors such as vascular endothelial
growth factor (VEGF), placental growth factor (PlGF), angiopoietin-1 (Ang 1), platelet-derived
growth factor-BB (PDGF-BB), and transforming growth factor 3 (TGF-p). 3 These factors can be
introduced directly into the blood stream or incorporated into cells, microstructures, or scaffolds
for more controlled release. 14 Alternatively, adenoviral vectors can be used to promote
angiogenesis by transferring genes that express angiogenic growth factors.
The second method aims to develop the microvasculature in vitro. This is typically done
by seeding a tissue-engineered scaffold with the appropriate cells to form new blood vessels.3
These vascularized scaffolds are then implanted, and the microvessels join with existing
vasculature in the host. While much work is being conducted in this area, clinical studies have
yet to be conducted on any scaffolds with pre-existing vascular networks. 14
2.2 Microfabrication Technologies
As researchers have continued to search for new strategies for engineering
microvasculature, some have begun to adapt technologies from other fields. One promising
method is the adaptation and use of microfabrication technologies to construct templates for
vascularized networks. Originally developed for the production of integrated circuits and
microelectromechanical systems (MEMS), microfabrication techniques enable the fabrication of
structures with a high degree of resolution. Microfabrication techniques have been further
developed over recent years to enable the printing and molding of elastomeric stamps. These
techniques, including replica molding, are referred to as soft lithography. 16
2.2.1 Photolithography
In microfabrication, photolithography is used to transfer a two-dimensional pattern onto a
given structure. A mask with the desired pattern is created using a computer aided design (CAD)
software package. Optical techniques are then used to transfer the mask pattern onto a substrate
on which the final structure is built through the deposition and etching of layers.' 7
The basic steps of UV photolithography are shown in Figure 3. The process begins with
a clean substrate on which a thin oxide film has been deposited. Alternatively, nitride,
polycrystalline silicon, aluminum, or noble metal films may also be used. Deposition techniques
include thermal oxidation, evaporation, sputtering, and various chemical vapor deposition
methods. A photoresist is then applied using one of a few possible methods: spin coating,
electrochemical coating, spray coating, or casting.18 In the most common process, spin coating,
a few milliliters of resist are applied to the wafer which is then spun to spread the resist into a
uniform layer. Photoresists can be divided into two types: positive and negative. In positive
resists, areas exposed to light become more soluble and are thus removed. In negative resists,
polymerization occurs in the regions exposed to light, and the unpolymerized regions are
subsequently removed. After applying the resist, the wafer is exposed to UV light and developed.
The film is then etched using wet or dry etching techniques, and the resist is stripped off to leave
the patterned film. Additional steps for priming, baking, and rinsing may also be added. 17
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Figure 3. Photolithography processing steps: (a) apply film for patterning to clean substrate; (b) spin-coat
resist onto film; (c) expose to UV; (d) develop; (e) etch film; (f) strip resist'7
2.2.2 Plasma Etching
Plasma etching is a dry etching technique that involves the excitation and ionization of
gases in a vacuum chamber. These gases in turn react chemically and physically with the film
surface. This method allows for more accurate anisotropic etching and thus the ability to pack
structures more closely. 18 In recent years, high aspect ratio micromachining (HARMS)
technologies have been developed that use deep reactive ion etching (DRIE) to etch channels of
even greater depths. Channels as deep as 40 and 400 pm have been etched with widths within +
0.1 and 1 pm, respectively. 19
2.2.3 Replica Molding
Replica molding, as its name implies, is a method of fabricating stamps and molds by
replicating the three-dimensional pattern from a solid substrate onto an elastomer. To produce
the replica mold, the prepolymer is cast over the patterned master and cured. The most
commonly used elastomers are siloxane-based polymers such as poly(dimethylsiloxane) (PDMS).
After curing, the newly patterned elastomer is peeled off; the use of an elastomer allows for
easier separation from the master, which is typically produced from a rigid material. The
polymer mold can then be used to pattern other materials. Features on the order of tens of
nanometers can be successfully reproduced using this technique.' 6
2.3 Draper's Technology
At the Charles Stark Draper Laboratory, researchers have applied microfabrication
techniques to the problem of engineering microvasculature for the regeneration of tissues and
organs. Masks have been designed based on microfluidic models of blood flow. These masks
are used to pattern silicon masters using traditional microfabrication techniques. Soft
lithography and polymer processing techniques are then used to make polymeric molds that are
subsequently joined to form the final closed microvascular networks. The basic fabrication steps
are shown below in Figure 4.
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Figure 4. Basic steps in fabricating Draper's microvascular networks: (a) design a mask using microfluidic
models; (b) use the mask to pattern a silicon substrate; (c) fabricate a PDMS template via replica molding; (d)
fabricate a PLGA template via compression micromolding; (e) thermal fusion bond PLGA templates to form
a closed network of channels22
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2.3.1 Fabrication of Master Molds
The fabrication of Draper's microvascular networks begins with the designing and
printing of photolithography masks. Fluid dynamic models (Figure 5) are produced to
approximate the behavior of blood flow in target organs. These models account for
physiologically important parameters including the non-Newtonian rheology of blood,
hematocrit, flow rate, pressure, and shear stress.20'2 1 These fluid dynamic models are then used
to design masks which are subsequently used to pattern silicon master molds (Figure 6) using
photolithography and plasma etching.
Figure 5. 2D microfluidic network model designed with a shear-based algorithm
Figure 6. Scanning electron micrograph of a vascular network etched on a silicon wafer; reprinted with kind
permission from Springer Science and Business Media21
2.3.2 Fabricating Polymer Templates
Once a silicon master has been fabricated, polymer templates can be produced using a
variety of techniques. PDMS templates are produced via replica molding; after casting, the
prepolymer is cured at 60-650 C for three to four hours.21,22 Plasma bonding is then used to bond
a patterned PDMS sheet to an unpatterned sheet resulting in a network of closed channels
(Figure 7).21 Alternatively, PDMS templates can be used as molds for the patterning of other
polymers. Poly(lactic-co-glycolic acid) (PLGA) templates have been produced via compression
micromolding. PLGA pellets are placed between PDMS molds and heated well above the glass
transition temperature. A compressive force is then applied to compression mold the PLGA melt
into the pattern on the PDMS templates. Thermal fusion bonding is then used to create closed
PLGA networks. This is done by the contacting of two layers and then subsequent heating to
just above the glass transition temperature; the interdiffusion of polymer chains bonds the two
layers together.22
Figure 7. Microfabricated PDMS network with a surface area of 13.69 cm2 , internal volume of 21.3 mm3,
channel depth of 35 pm, and channel widths ranging from 35 pm to 5 mm; reprinted with kind permission
from Springer Science and Business Media 21
2.3.3 Cell Seeding of Networks
Short term cell viability and proliferation have been demonstrated in fabricated PDMS
networks. The networks were sterilized, coated with purified collagen, and then seeded with
immortalized human microvascular endothelial cells (HMEC-1). Seeded networks were
incubated at 37°C with 5% CO2, and media was perfused through the network during incubation
using a system similar to the one shown in Figure 8. Cells reached confluence after
approximately one week in culture (Figure 9) and were maintained in culture for another week.21
Figure 8. Schematic of culture system used with PDMS networks21
(a [b
Figure 9. (a) Confluent layer of HMEC-1 cells in a PDMS network after approximately 1 week of culturing
(b) HMEC-1 cells after 2 weeks of culturing; reprinted with kind permission from Springer Science and
Business Media2 1
3 Technical Challenges & Considerations
Development of Draper's microvascular networks is still in the initial stages. Several
technical challenges remain to be overcome before the technology can be commercialized
including the selection of a final material, refinement of the network geometry, incorporation of
porosity, selection of surface coatings or modifications, optimization of cell culture on scaffolds,
and formulating the perfusion media. While some potential solutions for these challenges
already exist, research in these areas continues to produce new ideas for materials and methods.
Further experimentation will be necessary to determine whether current options are sufficient or
if further development of complementary technologies will be required to address Draper's needs.
3.1 Material Selection
When developing scaffolds for incorporation into the body, the efficacy is greatly
affected by the choice of material. Polymers are widely used in biomedical applications due to
the similarity of their physical properties to those of soft tissue. Additionally, polymers allow for
a large degree of tailoring of properties. While biodegradable polymers are typically preferred
due to their ability to degrade as new tissue is formed, non-biodegradable polymers are still used
for many applications which require mechanical properties not offered by biodegradable
polymers.23
For Draper's networks, a biodegradable polymer is desired for the final material selection.
While the biocompatibility of the material is important, some properties such anti-
thrombogenicity and cell adherence can be addressed with surface modifications if necessary.
Degradation properties will also play a key role in the decision making process. Considering the
fact that the proliferation phase of wound healing lasts for three weeks, the microvascular
network's degradation rate should be close to this length of time to provide support without
inhibiting the wound healing process. The method of degradation and degradation products will
also be important due to channel patency concerns and the perfusion of biomolecules through the
networks. The necessary mechanical properties for the networks still remain to be determined.
Research on engineering microvascular grafts typically stresses the importance of burst strength,
with values greater than that of saphenous veins (1700 mmHg) being desirable.24 The
compliance of blood vessels is also important as mismatch can induce intimal hyperplasia, thus
reducing patency. Compliance values for host artery and saphenous vein grafts are
approximately 5.9 and 4.4% per mmHg x 10-2, respectively. 25 While this may provide general
guidelines for appropriate mechanical properties, values are likely to differ for microvasculature.
Additionally, Draper's networks are not designed to be permanent; they must provide
mechanical support only until host cells have incorporated the networks into existing vasculature.
PDMS, a non-biodegradable polymer, was used for early phases of research at Draper
Labs because of its ease of use in fabricating microfluidic devices. 19 Work has since been
adapted to biodegradable polymers such as PLGA and poly(glycerol sebacate) (PGS).22,26 While
the ability to apply Draper's technology to biodegradable polymers has been demonstrated, the
selection of a final material with appropriate properties remains to be made. A wide range of
biodegradable polymers have shown potential for use in tissue engineering applications, and
researchers continue to develop polymers and copolymers with new combinations of properties.
A few of the main synthetic biodegradable polymers have been listed in Table 1 and will be
discussed along with natural polymers in considering the desired material properties for Draper's
vascularized networks.
Table 1. Synthetic biodegradable polymers for tissue engineering applications
2 7
'
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'
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Melting Point Glass DegradationPolymer Transition (C) Strength Time Degradation Products("C) Transition ("C) Time
7.0 GPaPoly(glycolic acid) 225 -230 35 -40 (modulus) 6-12 months Glycolic acid(modulus)
2.7 GPaPoly(1-lactic acid) 173 - 178 60 - 65 (modulus) >2 years L-lactic acid(modulus)
0.4 GPaPoly(caprolactone) 58- 63 -65 - -60 (modulus) >2 years Caproic acid(modulus)
8-40 MPa Lysine, glycolic acid,Polyurethane* -- - 1-2 months(tensile strength) caproic acid
Sufficient for load Diols, acids, &Poly(ortho ester)** - -10 - 10 Days to monthsbearing perntaerythritol
1.3 MPa 12 months(inPoly(anhydride)*** -- -MPa 12 months(in Dicarboxylic acids(modulus) vitro)
Poly(glycerol 0.3 MPa
sebacate) 5; 38 -- (modulus) 2 months Sebacic acid, glycerolsebacate) (modulus)
* Based on lysine diisocyanate & poly(glycolide-co-y-caprolactone)
** POE IV prepared with 5 mole % lactide, 3,9-diethylidene-2,4,8,10-tetraoxaspiro[5,5]undecane, and n-octanediol,
n-decanediol, or n-dodecanediol
** Poly[1,6-bis(carboxyphenoxy)hexane]
3.1.1 Aliphatic Polyesters
Poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and poly(caprolactone) (PCL) are
three of the most commonly used biodegradable polymers in biomedical research and
applications. PGA is a highly crystalline, and thus inelastic, polymer with a high tensile strength
and modulus. Because of its rapid degradation rate and low solubility in common organic
solvents, it is often combined with PLA to form PLGA. 14 PLA, a semi-crystalline polyester, also
possesses a high tensile strength and modulus but degrades at a slower rate and is easier to
process.30 Lactide has three isomers - L-lactide (LLA), D-lactide (DLA), and meso-lactide -
with LLA being preferentially metabolized by the body.27,30
By varying the ratios of PGA and PLA isomers used, PLGA with varying mechanical and
chemical properties can be obtained. PLGA is currently used in many formulations of
degradable sutures.30 A 90% glycolide and 10% L-lactide formulation sold by Ethicon as
VICRYL® (polyglactin 910) has also been used in the skin substitute Dermagraft. 30, 31
Degradation of PLGA by hydrolysis leads to the homogeneous erosion of amorphous and then
crystalline regions of the copolymer. 27
While certain properties of PLGA can be tailored simply based on the composition,
factors related to the interaction of PLGA with biomolecules and cells require more complicated
approaches for tailoring. Porous PLGA structures result in very rapid leaching of angiogenic
factors after incorporation. To enable slower and more controlled release of factors, PLGA
microspheres, beads, and bioactive foams have been fabricated.14 Another concern related to
biomolecules is their potential inactivation by the local accumulation of acidic degradation
products.27 These acidic degradation products have also been associated with adverse tissue
reactions in bony sites of the body.32 Finally, PLGA exhibits a limited affinity for cells. Thus,
additional coatings or surface modifications may be required to ensure proper cell attachment
and growth in certain tissue engineering applications. 26 While these concerns may necessitate
further processing techniques, they can still be addressed.
Other in vivo degradation properties of PLGA have proven to be more unavoidable,
which have caused it to be viewed as less than ideal for many tissue engineering applications
such as drug delivery. For instance, after implantation, PLGA undergoes a lag phase with
minimal mass change. This is followed by a rapid loss of mass via bulk degradation.
Mechanical strength, on the other hand, undergoes a sharp drop immediately after implantation.
Furthermore, as PLGA degrades, it swells and deforms significantly.33 These degradation
properties could potentially compromise flow through fabricated channels, thus suggesting that
another synthetic polymer may be more appropriate for use in Draper's networks.
Polycaprolactone (PCL) is another aliphatic polyester that has been widely studied in
addition to PLA and PGA. It is semicrystalline and has a much slower degradation rate, on the
order of two to three years.27 Therefore, it lends itself to more long term drug delivery
applications such as the contraceptive device, Capronor, which delivers zero-order release of
levonorgestrel for over a year.30 PCL also differs from other aliphatic polyesters in having
extremely low glass transition and melting temperatures but a high decomposition temperature of
3500 C; this could allow for easier processing of the polymer. While PCL homopolymers
degrade too slowly to be practical in this application, PCL can be used to form a wide range of
compatible polymer blends. 34 Many of these are now being studied for use in applications
including bone and vascular tissue engineering. 35,36' 37' 38
3.1.2 Polyurethanes
Polyurethanes (PUs) are a class of elastomers which have been used in larger diameter
vascular grafts and are now being developed for use in smaller diameter grafts. These polymers
are highly attractive for vascular tissue engineering applications due to their elastic and
compliant mechanical properties and biocompatibility. Many difficulties were encountered in
the initial development of PUs including hydrolytic instability, susceptibility to oxidative
degradation, and the toxicity of degradation products derived from some diisocyanate
components. Researchers have since developed newer generations of PUs that eliminate these
issues.27,39
Several PUs and PU composites are now in various stages of development. Thoratec
Corporation has commercialized a polyetherurethaneurea vascular access graft and is now
conducting clinical trials on the use of the material for small-diameter coronary bypass grafts.
Cardiotech International has also developed a family of poly(carbonate-urea)urethanes under the
trademarked name Chronoflex®.39
Saad et al. have developed a group of block copolyesters termed DegraPol". These
degradable polyesterurethanes are based on diisocyanates of PHB/HV-diol and PCL-diol or
Diorez®. While J774 macrophages and 3T3 fibroblasts cultured on Degrapol® exhibited lower
levels of cell adhesion and growth than cells cultured on tissue culture polystyrene (TCPS),
fibroblasts on Degrapol" produced more ECM. When implanted subcutaneously in rats,
moderately thick fibrous capsules (60-250 jm) formed. Additionally, implants were reduced to
approximately 50% of their molecular weight after one year.36 While these results suggest
moderate biocompatibility, the degradation rate may be slower than desired.
Another group of poly(ester-urethane)ureas (PEUUs) have been developed by Guan et al.
These PEUUs are synthesized from PCL and 1,4-diisocyanotobutane with lysine ethyl ester or
putrescine chain extenders. Excellent mechanical properties and human umbilical vein
endothelial cell (HUVEC) viability and proliferation have been demonstrated on unmodified and
RGDS-modified PEUUs.
Williamson et al. have developed a porous scaffold for small diameter grafts using
gravity spun PCL fibers wrapped around a stainless steel mandrel and coated with electrospun
PU. The PCL fibers are spun with a fiber-to-fiber gap of 1-5 jim, and the PU anti-luminal
surface is characterized by 10-30 pm pores. HUVECs and smooth muscle cells (SMCs) both
exhibited good attachment to the scaffolds.38
PU composites are also being developed for use in skin substitutes. For example, Bruin
et al. have constructed lysine diisocyanate (LDI)-based poly(glycolide-co-&-caprolactone)
urethane networks which degrade within four to eight weeks. Ninety to 250 jIm pores were
formed using salt leaching techniques, and a non-porous polyetherurethane layer was glued on
top to form a bilayered skin substitute approximately 2 mm thick.40
3.1.3 Poly(ortho esters)
Poly(ortho esters) (POEs), developed by Alza Corporation, are a group of hydrophobic
polymers with hydrolytically sensitive backbones. The high degree of hydrophobicity prevents
water penetration and results in slow degradation by surface erosion. Consisting of four different
families, these polymers have primarily been developed for use in drug delivery. POE I is
synthesized from diols and diethoxytetrahydrofuran, POE II from diols and a diketene acetal, and
POE III from a triol and ortho ester. POE IV is a modification of POE II that includes segments
of lactic or glycolic acid in the backbone to aid in degradation of the polymer. 30
Of the four families, POE IV is the only polymer which appears to have the
characteristics necessary for commercialization. Synthesis of POE IV is simple and reproducible,
the polymer possesses appropriate thermal and mechanical properties, and degradation rates can
be varied from a few days to months. Degradation occurs through surface erosion, resulting in
the linear weight loss and release of lactic and propionic acid. The mechanism for degradation
also prevents the interior of the polymer matrix from becoming highly acidic as is common with
PLGA.29 While surface erosion would allow networks to maintain their structure and strength as
they degraded, the high degree of hydrophobicity in POE IV could potentially inhibit the proper
delivery of nutrient medium to cells within the scaffold.
3.1.4 Polyanhydrides
Polyanhydrides are another group of surface-eroding polymers. Because of their poor
mechanical properties and rapid degradation rate, they have been studied primarily for use in
drug delivery applications. Their degradation, which is dependent on both polymer structure and
the monomers used, can be slowed by the incorporation of aromatic carboxylic acids in place of
aliphatic ones. 30 Mechanical properties can also be significantly enhanced by copolymerization
with polyimides. In these poly(anhydride-co-imides), hydrolysis of the anhydride bonds occurs
first, followed by the imide bonds.27
3.1.5 Poly(glycerol sebacate)
As previously mentioned, Draper has also fabricated vascularized networks using PGS.
PGS, a biodegradable and biocompatible elastomer developed by Wang et al., possesses
mechanical properties similar to those of veins.26 It has been suggested that it degrades primarily
through surface erosion since it exhibits a gradual loss of mass and mechanical strength.28'33
Endothelial cells adhere to PGS, but surface modification with GRGDS peptides increases
uniformity of distribution and adhesion.26 The in vivo biocompatibility of PGS has been tested,
and it exhibits responses comparable to, if not better than, PLGA for inflammation and fibrous
capsule formation.28
While the mechanical properties of PGS would be more relevant to blood vessel grafts
immediately connected to a host's vasculature, a stronger material may allow earlier inosculation
of microvascular networks by mechanically supporting the blood vessels before they fully
mature. Another potential advantage of PGS is that it exhibits surface erosion but also has a
hydrophilic surface.28 Fabrication of PGS microvascular networks has already been
accomplished, and although the size and uniformity of the pores is unknown, porous scaffolds
have also been fabricated separately through salt leaching.26' 28
3.1.6 Natural Polymers
The use of natural polymers in tissue engineering applications has obvious appeal due to
their excellent biocompatibility. For example, collagen, the most abundant protein in the human
body, has been incorporated into various skin substitutes including Integra, Apligraf, and Orcel.30
Benefits of using collagen in matrices include its natural abundance in skin, promotion of
cellular adhesion and proliferation, and its ability to be cross-linked to increase mechanical
strength. Because collagen is typically present in later stages of wound repair, some have
suggested that it may not be the optimal material for cell migration. 12 However, in addition to
cell surface receptors, type I collagen is highly porous (50-150 pm pores); this suggests that the
late appearance of collagen in wound repair may not be a substantial issue.14 An additional
concern with regards to the use of collagen may be its high thrombogenicity. 30
Another natural polymer highly researched for wound healing applications is hyaluronic
acid. While it is a known mitogen and motogen of mesenchymal and epithelial cells, cell
adherence to the material is poor.14'30 Additionally, its degradation products are angiogenic, but
HA itself inhibits endothelial cell proliferation. Modifications to address these issues include
adding RGD sequences and cross-linking with chitosan, another GAG. Chitosan attracts
neutrophils and activates macrophages. The HA-chitosan combination has been used in research
to make human skin equivalents. 14 Although natural polymers are typically more biocompatible
than synthetic ones, they also raise additional concerns such as antigenicity and batch-to-batch
variation.30
3.2 Network Geometry
While microfabrication techniques have been successfully used to create three
dimensional polymer networks, a significant amount of process refinement still remains to be
carried out. One example is the further enhancement of channel geometry. Currently, channels
with varying widths but uniform depths have been fabricated, resulting in rectangular cross-
sections (Figure 10). While the effect of geometry on flow, pressure changes, and turbulence is
currently being assessed, it can be assumed that, considering the actual geometry of blood
vessels, cylindrical channels would be preferred. The processing changes required to accomplish
this are fairly straightforward; cylindrical channels can be formed by bonding two patterned
polymer templates, each with a semicircular trench.21 Though straightforward, the
micromachining of semi-circular channels may be a lengthy process as it requires the deposition
and etching of many layers.
Figure 10. Cross-section of a bonded PGS capillary; reprinted with permission from Mary Ann Liebert,
Inc.26
Enhancement of the three dimensional architecture of networks may also be worth
consideration. Currently, two dimensional networks are stacked to form the three dimensional
networks; the inlets and outlets connect the ends of all of the two dimensional networks.
Therefore, the branching of the vasculature still primarily occurs in two dimensions. Additional
studies will need to be conducted to assess the effect of this on the efficacy of the networks.
3.3 Porosity
Another related technical challenge that must be addressed is the incorporation of
porosity into the matrix surrounding the networks in order to facilitate the migration of cells and
diffusion of perfusion media throughout the matrix. Techniques for the fabrication of porous
scaffolds via solvent casting are currently being investigated at Draper for this purpose.
Considering the processes involved in fabricating the vascularized networks, such as replica and
compression molding, steps for introducing porosity will likely be carried out after channels are
formed. Additionally, pores of differing sizes may be desired for different areas of the construct.
Macropores (-500 pm) regulate cell type and seeding density, mesopores (-20-30 ipm) allow for
the infiltration of microvessels, and micropores (< 10 pin) regulate molecular transport. 14
Studies by Matsuda and Nakayama have found that for a range of micropored segmented
polyurethane films (SPU) with constant pore area per unit area, pore diameters between 18 and
50 rpm were optimal for endothelialization with bovine thoracic aorta ECs. Complete
endothelialization was achieved after two days for all pore sizes tested between 18 and 100 pm
while migration through 9 pm pores was significantly retarded. Other studies have shown that
SPU prostheses with pores sizes less than 15 pm, between 15-45 lm, and greater than 50 ipm
result in minimal, fibrohistiocytic, and organized fibrous tissue growth, respectively. 41
In fabricating complete devices for tissue engineering applications, pores of at least 100
pm would be desired in the polymer scaffold surrounding the channel networks. Here the
porosity would serve mainly to facilitate the migration of cells and ingrowth of tissue. In the
case of materials such as PU, porosity could also increase the flexibility of the material and thus
allow for better compliance matching with blood vessels. 41 Depending on how well media is
able to diffuse through the polymer used, micropores may also be formed in the channel walls to
provide initial vascular permeability. Blood vessels must exhibit some degree of permeability to
allow the transport of macromolecules. This is especially important for Draper's channel
networks as the perfusion medium will not only deliver nutrients and oxygen, but also growth
factors to enhance angiogenesis and wound healing in the area. Permeability, however, must be
carefully controlled to prevent imbalances in oncotic pressure, osmotic pressure due to
macromolecules, which can lead to edema.3
3.4 Coatings and Surface Modifications
Coatings and surface modifications of tissue-engineered devices typically serve two main
purposes: providing an anti-thrombogenic surface and/or promoting specific cellular functions.
The issue of thrombogenicity arises with all tissue engineering devices that are in direct contact
with blood. While a variety of anti-thrombogenic coatings are available and used in vascular
grafts, using ECs as a coating may be preferred for Draper's technology. While this does present
added challenges and complications, cells will eventually be necessary components in the
networks if any significant amount of tissue synthesis is to be carried out in vitro. In addition to
issues regarding maintaining cultures, additional coatings or surface modifications may be
required to promote cell attachment and growth on the channels and in porous regions.
Materials which promote cell attachment typically have receptors for many different cell
types. Additionally, simple methods for coating various materials with preclot, fibronectin,
gelatin, or collagen have shown mixed results in improving EC adhesion.42 Thus, in order to
improve cell selectivity on various parts of the networks, surface modification with cell adhesion
ligands may be preferred over coatings of actual cell adhesive materials. In considering surface
modifications, the specific ligand type, spacer length, and peptide surface concentration are all
important factors.
Hubbell et al. touch upon each of these issues in their study of the attachment of human
foreskin fibroblasts (HFFs), human vascular smooth muscle cells (HVSMCs), HUVECs, and
quiescent and activated human blood platelets.43 Glycophase glass and PEG-modified PET
surfaces were functionalized at concentrations of 10 pmol/cm2 and 20 finol/cm 2, respectively,
with four different peptide sequences: Arg-Gly-Asp (RGD), Tyr-Ile-Gly-Ser-Arg (YIGSR), Pro-
Asp-Ser-Gly-Arg (PDSGR), and Arg-Glu-Asp-Val (REDV). RGD is a cell-binding ligand found
on many cell adhesion proteins while YIGSR and PDSGR are found on laminin and REDV is
found on fibronectin. Results suggested that HVSMCs require higher concentrations of ligand
(>20 fmol/cm 2) than HFFs, and all cell types require higher concentrations of PDSGR than RGD
and YISGR to adhere to surfaces. Additionally, REDV selectively promotes the adhesion of
HUVECs. These results are consistent with other studies showing that at least 10 fmol/cm2
GRGDY is required for human fibroblast spreading. While platelets have also been shown to
adhere to RGD-functionalized surfaces, it was suggested that this is only the case with longer
spacer lengths.43 The results from this study suggest that REDV may be an appropriate ligand for
the surface modification of channels while RGD or YIGSR could be used to modify the porous
regions surrounding the channels.
3.5 Cell Seeding
When pre-seeding vascular networks in vitro, endothelial cells will likely be the primary
cells of concern as they line all blood vessels and are the only cells found in small capillaries. 44
However, a combination of cells may be needed to optimize the subsequent growth of cells and
tissue on the networks. For example, much research indicates that while blood vessel and tissue
growth can be induced with ECs alone, the vessels produced are typically unstable and do not
last very long. 3 Additionally, human ECs require the addition of angiogenic factors such as
phorbol 12-myristate 12-acetate (PMA), basic fibroblast growth factor (bFGF), VEGF, and fetal
calf serum (FCS) to form blood vessels. Some factors, including PMA, are known to promote
tumors and thus not likely to be used in clinical applications. Better results, however, have been
achieved through co-culturing with fibroblasts. Fibroblasts are able to synthesize greater
quantities of ECM and enable the formation of more stable, functional blood vessels. 45
The synergistic effects of co-culturing cells are likely due to cell-cell and cell-matrix
interactions, both of which help to regulate angiogenesis. HUVECs produce a very limited
amount of ECM when cultured alone while fibroblasts are capable of producing substantial ECM
when cultured alone.4 5 Thus, in addition to providing cell-cell interactions, co-culturing of cell
types may also allow for improved EC cell-matrix interactions on synthetic polymer networks.
While the majority of research on the development of vasculature in vitro focuses on
various types of differentiated ECs, some researchers are now suggesting the use of endothelial
progenitor cells (EPCs) instead. EPCs, which differentiate into ECs, can be isolated from adult
peripheral blood.46 While they are found in extremely low concentrations, cultured populations
can be doubled more than 1,000 times. Mature ECs, on the other hand, senesce after
approximately thirty doublings.47 EPCs are capable of vasculogenesis via in situ incorporation,
differentiation, migration, and/or proliferation without additional angiogenic factors.46 The
seeding of EPC-derived ECs and SMCs onto PGA-PLLA scaffolds in studies by Wu et al. have
resulted in the formation of layered tissue containing microvessels. Other studies have also been
conducted to demonstrate the endothelialization of gelatin-coated PU grafts by EPCs.47
In considering the application of vascular networks to cutaneous wound healing
applications, seeding with keratinocytes could also be used to enhance reepithelialization. If
used, these cells would be seeded on the top surface of the microvascular networks after seeding
with ECs and fibroblasts. The effects of keratinocyte seeding density have been previously
studied by Butler et al. using a collagen-GAG matrix. In order to achieve confluence of
uncultured autologous keratinocytes in two weeks, a seeding density of at least 100,000 cells/cm2
was required. This seeding density allowed for a 30-fold expansion over the donor site surface
area.48 A subsequent study revealed that proliferation increases when autologous keratinocytes
are cultured prior to seeding.13 Thus confluence can be achieved with lower seeding densities if
cultured keratinocytes are used instead. After the determination of cell sources and cell types to
be cultured on Draper's microvascular networks, additional experiments will be necessary to
optimize seeding densities for each cell type.
3.6 Perfusion Media
The optimization of medium formulations for perfusion also presents a significant
challenge. Appropriate combinations and concentrations of biomolecules must be determined in
order to sustain cell viability, regulate specific cell functions, and promote angiogenesis.
Furthermore, the incorporation of antimicrobial components such as silver nanoparticles may be
desirable as this could eliminate the need for additional antibiotics. In order to promote
angiogenesis, a variety of growth factors should be considered for addition to the perfusion
media. Table 2 lists the major growth factors known to be involved in angiogenesis. Because
angiogenesis is an essential part of wound repair, many of the same growth factors are found in
healing wounds (Table 3).
Table 2. Angiogenic growth factors
1 4
'
49
Growth Factor Function
FGF-1 EC, SMC, & fibroblast mitogen & chemotactic
FGF-2 EC mitogen & chemotactic
VEGF-A EC mitogen & motogen
VEGF-B EC mitogen & motogen
VEGF-C Venous & lymphatic mitogen
VEGF-D Venous & lymphatic mitogen
TGF-P3 Angiogenic sprouting
PDGF Vessel maturation; SMC & fibroblast mitogen
Ang-1 Vessel maturation - thickening; EC sprouting
Ang-2 Vessel maturation - thinning
FGF - fibroblast growth factor; VEGF - vascular endothelial growth factor; TGF - transforming growth factor;
PDGF - platelet-derived growth factor; Ang - angiopoietin
Table 3. Wound healing growth factors9'10, 50
Family Growth Factor Primary Sources Primary Target Cells & Effect
EGF Platelets Keratinocyte motogen & mitogen
Epidermal growthEpidermal growth TGF-a Macrophages; keratinocytes Keratinocyte motogen & mitogenHB-EGF Macrophages Keratinocyte & fibroblast mitogen
FGF-1 (aFGF)Fibroblast growth FGF- (FGF) Macrophages; endothelialFGF-2 (bFGF) cells Angiogenesis; fibroblast mitogen
factor (FGF) FGF-4
FGF-7 (KGF) Fibroblasts Keratinocyte motogen & mitogen
TGF-31 Keratinocyte motogen; chemotactic for
Transforming growth Platelets; macrophages macrophages & fibroblasts; ECM synthesis &
factor P (TGF-P) TGF-12 remodeling
TGF-P3 Macrophages Antiscarring
Platelet-derived Chemotactic for macrophages & fibroblasts;
growth factor (PDGF) / PDGF keratinocytes macrophage activation; fibroblast mitogen; matrix
vascular endothelial production
growth factor (VEGF) VEGF Macrophages; keratinocytes Angiogenesis
Insulin-like growth IGF-1 Plasma; platelets Endothelial cell & fibroblast mitogenfactor (IGF)
Interleukins (ILs) IL-la & [ Neutrophils Early activator of growth factor expression in
macrophages, keratinocytes, & fibroblasts
Colony stimulating CSF-1 Multiple cells Macrophage activation and granulation tissue
factor (CSF) ellsproduction
Other TNF-a Neutrophils Similar to IL-ls
Other Activin Fibroblasts; keratinocytes Unknown
Other CTGF (CCN2) Fibroblasts; endothelial cells Fibroblasts; downstream of TGF-31
HB-EGF - heparin-binding epidermal growth factor; aFGF - acidic FGF; bFGF - basic FGF; KGF - keratinocyte growth factor;
TNF - tumor necrosis factor; CTGF - connective tissue growth factor
Fibroblast growth factor (FGF), the first angiogenic growth factor to be discovered, is
part of a family of growth factors consisting of at least 20 molecules. FGFs are produced by
vascular ECs and SMCs and have been found to stimulate both EC and fibroblast growth. FGF-
1, also known as acidic FGF (aFGF), is involved in capillary progression, wound healing, and
tumor progression.49 FGF-2, also referred to as bFGF, is essential in early wound repair
processes occurring in the first three days. l0 Together with vascular endothelial growth factor
(VEGF), these two growth factors bind to fibrin to retain bioactivity and synergistically promote
angiogenesis.12, 49
Included in the platelet-derived growth factor (PDGF) / VEGF family are the growth
factors PDGF, VEGF, and PlGF. 9, 49 PDGF is both the most potent mitogen in serum for
mesenchymally-derived cells, such as fibroblasts and SMCs, and a strong chemotactic for
inflammatory cells. It consists of two polypeptide chains, A or B chains, which give rise to its
three isoforms: PDGF-AA, PDGF-BB, and PDGF-AB.51 Its concentration in human serum is
estimated at 15-50 ng/mL with maximum chemotaxis or activation of various cell types at
varying concentrations. Lower concentrations of 1-5 ng/mL and 10-20 ng/mL are optimal for
neutrophil chemotaxis and SMC and fibroblast attraction, respectively. A concentration of 20
ng/mL allows for maximum monocyte chemotaxis, and even higher concentrations of 20-40
ng/mL activate neutrophils.52 Johnson & Johnson Wound Management Worldwide produces the
only FDA-approved recombinant human growth factor product currently on the market in its
REGRANEX® (becaplermin) gel. With 0.1% recombinant human PDGF-BB (rhPDGF-BB),
REGRANEX® promotes the healing of diabetic foot ulcers.9'53 VEGF is another growth factor
essential to proper wound healing with VEGF-A, or VEGF165, being the most common human
isoform.49 It induces the local formation of blood vessels and thus becomes important once
granulation tissue begins to form around days four to seven.10' 32 The regulation of VEGF is
affected by conditions such as hypoxia and a wide range of other growth factors including PDGF,
tumor necrosis factor a (TNF-a), FGF-2, FGF-4, FGF-7, transforming growth factor P (TGF-p),
angiotensin-2, insulin-like growth factor-i (IGF-1), interleukin-1 (IL-1), IL-6, IL- 10, IL- 13,
Ang-1, and Ang-2.49
The TGF-3 family is another group of growth factors involved in angiogenesis and
wound healing. TGF-01, TGF-p2, and TGF-P3 are all present in low, if not undetectable, levels
in the plasma of unwounded skin. However, upon injury, the concentration of these factors
elevates, with TGF-31 having the highest concentration of about 30 ng/mL. TGF-P2 and TGF-
P3 are found in much lower concentrations of 1-1.5 and 1-2 ng/mL, respectively.54 It has been
suggested that TGF-31 and TGF-02 are related to scarring and inflammation in adults. 9' 49 This is
due to observations that the factor is present in high concentrations in adult wounds in which
these two phenomena occur but in relatively low concentrations in embryonic wounds, which
heal without these phenomena. TGF-P31 and TGF-P2 concentrations can both be down-regulated
in wounds through the application of TGF-P3.50 In addition to this function, studies by
Bandyopadhyay et al. have also suggested that TGF-P3 may be involved in the regulation of
epidermal and dermal cell migration during wound healing. They have observed that plasma
(from unwounded skin) promotes the migration of dermal fibroblasts and human dermal
microvascular ECs (HDMECs) while serum (from wounded skin) promotes the migration of
keratinocytes. This effect has been attributed to the increased levels of TGF-13 in serum.54
The therapeutic use of growth factors must be carefully controlled to prevent pathological
angiogenesis. For example, excessive amounts can lead to fibrovascular growth.14 However, the
external regulation of growth factors may prove to be a difficult task due to interactions with
different receptors and other growth factors. As previously mentioned, VEGF is affected by
many growth factors, and TGF-P3 can regulate TGF-131 and TGF-P2. Other examples of these
interactions include the ability of TGF-1 to stimulate or inhibit angiogenesis depending on
whether its receptor is activin-like kinase type-1 or type 5 (ALK-1 or -5) and the ability of Ang-2
to antagonize Ang-l but also promote neovascularization when combined with VEGF. 14,49
In developing a formulation for perfusion media, a balance will need to be found between
using more growth factors to promote a faster response and using fewer factors to limit costs and
unknown effects from growth factor interactions. PDGF, VEGF, and TGF-P3 will likely be the
primary components used in promoting angiogenesis. The addition of FGF-2 may not be
essential as it is more important in the very early stages of wound healing. TGF-l1 and TGF-32
may also be excluded to limit scarring and inflammation as the wound heals. For chronic wound
healing applications, the addition of EGF, TGF-a, and FGF-7 may be desired as these factors
have been shown to promote reepithelialization when applied exogenously.50
Another issue of concern is the concentration of growth factors required to achieve a
positive response. In vitro, human endothelial cells require a greater amount of growth factors
than animal equivalents such as bovine or rat cell cultures. 45 If large concentrations of factors
are required over extended periods of time to promote wound healing, this method of treatment
may prove to be economically infeasible. On the other hand, one benefit of the incorporation of
growth factors into the medium instead of the scaffold itself is that concentrations can be varied
as the wound enters different phases of tissue growth and remodeling. Ideally, the
concentrations of the various factors in the perfusion media will match those found naturally in
acute wounds. While studies to determine these values have yielded widely varying results, they
provide a starting point for estimating appropriate concentrations. 52,54,55,56'57 Based on these
studies, a suggested preliminary formulation to be tested is as follows: 50 ng/mL PDGF, 3
ng/mL VEGF, 2 ng/mL TGF-p3, 2 ng/mL TGF-a, and 50 pg/mL EGF.
Finally, flow characteristics of the media as it is perfused throughout the networks must
also be considered. One characteristic which has already been addressed to some extent by the
microfluidic models is shear stress on vessel walls. Areas of lower shear are associated with the
development of atherosclerosis. Thus, Draper has designed its networks to have constant shear
rates throughout the networks. 20 Shear stress is also an important factor due to its effects on EC
morphology and function. ECs have been found to elongate and align in response to flow.
Additionally, higher levels of shear stress result in decreased cell proliferation, the up-regulation
of the expression of some genes, and the down-regulation of others. Cyclic stretch resulting
from pressure pulses is another important factor. While cyclic stretch can also contribute to EC
elongation and orientation like shear stress, other effects contrast with those produced by shear
stress.5 s While all cell studies of Draper's networks to date have used constant flow for
perfusing media, further experiments should be conducted to determine whether a pulsatile flow
yields better results.
4 Chronic Wound Healing Applications
4.1 Chronic Wounds
Approximately 7 million people in the United States suffer from chronic wounds
including bums, diabetic ulcers, venous stasis ulcers, and pressure ulcers. As the population ages,
concerns and costs of treating these conditions will continue to grow. While it would be ideal to
regenerate tissue with the same structure and function as the tissue prior to wounding, the quality
of life of many patients could be greatly improved by simply developing methods to more
rapidly close wounds. While many advanced wound care products have been developed for this
purpose in recent years, most of these products still only enhance chronic wound closure or
healing rates by about 25%.12 As advances are made in technology and the understanding of the
pathophysiology of chronic wounds, better products will become available for treating the
various types of chronic wounds.
4.1.1 Bums
Each year, approximately 70-100,000 individuals are hospitalized for burn injuries in the
United States. These injuries are typically on the head, neck, and upper extremities, and
rehabilitation can continue for 1-2 years after injury.8 In severe bums, dermal tissue promotes
the growth of scar tissue instead of the regeneration of normal dermis. If the wound is closed
without an underlying dermis - for example, through the application of split-thickness autografts
- the resulting skin may exhibit fragility, blistering, and hypertrophic scarring. Thus advanced
wound dressings aim to inhibit the growth of scar tissue while promoting normal dermal tissue
regeneration. 59
4.1.2 Venous Stasis Ulcers
Venous ulcers are the leading cause of leg ulcers in the western world and affect
approximately 600,000 Americans. 12,60 These ulcers are typically located on the medial
malleolus, the bony prominence of the ankle, and result from chronic venous insufficiency, the
failure of veins to properly pump blood back to the heart. 60 Blood pools in veins of the legs,
leaks out of the vessels into surrounding tissue, and eventually causes the formation of an ulcer."
4.1.3 Diabetic Ulcers
It is estimated that 21 million Americans suffer from diabetes. Up to 10%, or 2 million,
diabetics develop foot ulcers, typically in the weight bearing or stressed areas of the foot, and
each year, approximately 82,000 require amputation due to complications such as infection. 12
Diabetics commonly form chronic foot ulcers due to changes in the bone architecture of their
feet, peripheral neuropathy, and atherosclerotic disease in the lower limbs.62 Peripheral
neuropathy or sensory impairment prevents diabetics from recognizing mechanical pressure
which eventually leads to injury of the skin.61 Arteriosclerosis in the lower limbs may contribute
to peripheral neuropathy by blocking the blood vessels supplying nerves in the region; it can also
lead to ischemia, or the deficiency of oxygen in tissues, which in turn may inhibit the healing
process once an ulcer forms. 62 Other abnormalities which have been observed in the healing of
diabetic ulcers include prolonged inflammation, impaired neovascularization, decreased collagen
synthesis, increased protease levels, and defective macrophage function. 1o
4.1.4 Pressure Ulcers
As their name implies, pressure ulcers, also referred to as decubitus ulcers or bedsores,
are caused by prolonged excessive pressure on an area of the body. This pressure in turn leads to
ischemia and eventually tissue necrosis. Over 95% of pressure ulcers develop over bony
prominences on the lower half of the body. There is a wide variation in estimates of incidence
and prevalence rates of pressure ulcers among patient populations. In acute settings, the
incidence of pressure ulcers ranges from 3-14%, and the prevalence ranges from 9-18%.
Prevalence rates are higher in certain patient populations including the elderly and patients with
spinal cord injury. 63 Overall, an estimated 1.4 million individuals in the U.S. suffer from
pressure ulcers.12
4.2 Market Analysis
In 2004, revenues from the U.S. medical device market were estimated at $63.76 billion.
Of this, $3.16 billion, or approximately 5%, was generated by the wound care and management
market (Figure 11). With a forecasted compound annual growth rate (CAGR) of 6.1% (Figure
12), revenues are estimated to reach $4.76 billion by 2011. 64
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The wound care and management market can be further segmented as shown in Figure 13.
The total revenues of the interactive wound dressing market increased from $75.8 million to
$84.5 million from 2004 to 2006, and it is estimated that with a CAGR of 11.7%, revenues will
reach $182.8 million by 2013.65 While Draper's technology would enter the interactive wound
dressing market, it would still compete with other wound care segments which contain products
used to treat chronic wounds. Some complementary use would also occur due to the fact that
interactive wound dressings, including Draper's potential product, are typically secured with
traditional dressings. With over a dozen major participants in the interactive wound dressing
market alone (Table 4), the market is highly competitive. 64
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Figure 13. Wound care and management market: segmentation and corresponding revenues in 200464
Table 4. Major participants in the interactive wound care market65
Skin Substitute Companies Biomaterial Dressings Companies
Advanced Biohealing Biocore
Cook Biotech Brennen Medical
Genzyme ConvaTec
LifeCell The Hymed Group Corporation
Organogenesis Integra Life Sciences
Ortec International, Inc. Johnson & Johnson Ethicon
TEl Biosciences UDL Laboratories
4.3 Competitive Technologies
4.3.1 Grafts
Skin grafts are one of the oldest and most widely used methods for treating bum wounds.
Autografts, which involve removing skin from one area on an individual to cover wounds on
another area, are preferred but greatly limited in availability. Split-thickness skin grafts (STSGs)
remove the epidermis and a superficial portion of the dermis from a donor site. While the graft
can be meshed to increase the covered surface area by 1.5-3 times, this compromises functional
and aesthetic results of the graft. STSGs allow for serial reharvesting from the same donor site.
However, more dermis is taken each time, resulting in longer healing times. Full-thickness skin
grafts can also be harvested. While this reduces the scarring at the graft site, it increases the
scarring at the donor site.13 A thicker dermis also increases the difficulty of delivering nutrients
to the epidermis thus reducing the chances of the survival of the epidermis. 24 With all autografts,
donor site morbidity, including pain, scarring, and hypo- or hyper-pigmentation, is of great
concern. Additionally, not all grafts are successful; shear, infection, or fluid accumulation may
prevent a graft from taking.13
Due to availability restrictions, allografts from cadaver skin and xenografts from porcine
and bovine skin are often used as temporary treatments. While these grafts adhere to wounds for
several weeks and promote angiogenesis, they are eventually rejected by the body and therefore
require eventual removal and autologous regrafting.66
4.3.2 Interactive Wound Dressings
The demand for products which enhance healing rates has led to the development of a
variety of interactive wound dressings. Two main categories of products are currently offered
commercially: skin substitutes and biomaterial-based products. Skin substitutes are designed to
temporarily or permanently replace lost skin; major participants in the market include Advanced
Biohealing, Inc., Genzyme Corporation, Integra LifeSciences, LifeCell Corporation,
Organogenesis, and Ortec. 65 Some of these are based on allografts and xenografts that have been
treated to remove cellular components and typically also the epidermis. This leaves behind an
acellular dermal matrix that will not cause an immune response. 67 These products, which are
cryopreserved, have shelf lives of two years; examples include AlloDerm®, E-Z DermTM ,
GammaGraft®, and GRAFTJACKET® (Figure 14).11,68 Other skin substitute products (Table 5)
are fabricated using ECM components and/or cells.
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Figure 14. (a) Graphic of AlloDerm ® acellular matrix components and (b) application of GRAFTJACKET®
to a wound 69,
70
Table 5. Skin substitutes6 5,6 7' 7 -81
Product Degree of Dermal Epidermal
Product Company Description Porosity Fibroblasts Keratinocytes Permanance Shelf Life
Apligraf Bilayered living skin Can be Permanent;(Graftskin) equivalent meshed bioresorbable
UDL Silicone film bonded Temporary;Biobrane Laboratories to collagen-bound Mesh N N peeled off after -3 years
nylon fibers healed
Advanced Dermal substitute-
Dermagraft BioHealing fibroblasts, ECM, & Mesh Y N Permanent; 6 monthsAdvanced polyglactin scaffold bioresorbable
Tissue Sciences polyglactin scaffold
Cultured epidermal
Genzyme autograft on Permanent;Epicel Biosurgery petroleum gauze Nonporous N Y gauze 1 day
backing removed
Collagen & Permanent
Integra chondroitin-6-sulfate dermis;LifeSciences ECM wsilicone temporary 2 years
backing epidermis
Heathpoint Acellular porcine
OASIS CH thB intestinal submucosa Porous N N Permanent; 2 yearsCook Biotech matrix bioresorbable 2 yearsmatrix
Porous
OOrtec Bilayered bovine dermis & Permanent;OrCel International collagen sponge & non- Y bioresorbable 9 months
gel cellular matrix porous
epidermis
PriMatrix TEI Biosciences Acellular fetal bovine Can be Permanent;
dermal matrix meshed bioresorbable
AdvancedTransCyte BioHealing ECM-coated nylon Temporary;(Dermagraft Advanced mesh embedded in Mesh Y;nobn- N used prior to 1.5 years
-TC) Tissue Sciences silicone membrane autografts
Epicel® is a cultured epidermal autograft (CEA) consisting of two to eight layers of
autologous keratinocytes supported by a petrolatum gauze backing. The cells are acquired from
a 2 x 6 cm full-thickness biopsy and cultured on irradiated murine cells. 71 The process of
culturing the cells takes two to three weeks, but the shelf life of the final product is only one
day. 66,72 Another disadvantage is the high cost, approximately $825 per 50 cm2. 72 As a result, it
is primarily used for patients with life-threatening, high surface area burns.66 Because of the lack
of a dermal component, Epicel® is very fragile and may necessitate the use of an additional
dermal substitute.67,72
Several other products currently on the market incorporate allogeneic cells to provide
immediately available alternatives. One example would be Dermagraft®, a dermal substitute
designed to treat diabetic foot ulcers. It consists of a polyglactin mesh seeded with human
neonatal foreskin fibroblasts. 73 The cells are cultured on the mesh for approximately three weeks,
and the final product is supplied in 2" x 3" cryopreserved sheets.66'73 TransCyteTM , formerly
Dermagraft-TC, is a temporary dermal substitute for use on burn wounds prior to autografting. It
is comprised of a 5" x 7.5" nylon mesh coated with bovine collagen and bonded to a silicone
membrane.74 While this matrix is also seeded with fibroblasts, the cells are non-viable when the
product is used.66
Living skin equivalents such as Apligraf® and OrCel® incorporate both allogeneic
fibroblasts and keratinocytes to provide dermal and epidermal components. Apligrafe (Figure
15), formerly Graftskin, was the first tissue-engineered skin to receive FDA approval. 72' 75 It is a
circular, bi-layered skin substitute with a diameter of 75 mm. The dermal component is
comprised of fibroblasts seeded in bovine type I collagen, and the epidermal component is
formed by allowing keratinocytes to proliferate and differentiate on the dermis. The layers of
skin are reproduced in Apligrafe but without blood vessels, hair follicles, sweat glands, or other
cell types such as melanocytes, Langerhans' cells, macrophages, and lymphocytes. 76 OrCel®
consists of a porous, bovine type I collagen sponge matrix coated with a collagen gel coating on
one side. The sponge region is seeded with dermal fibroblasts while the non-porous gel side is
seeded with keratinocytes.66 It is available fresh or cryopreserved, both of which are FDA-
approved for the treatment of epidermolysis bullosa (EB) and burn autograft donor sites.66 '77 In
addition, successful Phase III clinical trials have been completed for the use of the cryopreserved
product on venous leg ulcers, and premarket approval (PMA) is now being sought. Clinical
trials for the use of OrCel® on diabetic ulcers are also being conducted."1 While both Apligrafe
and OrCel® provide an epidermal and dermal component, both components combined are less
than 1 mm thick.66
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Figure 15. Apligraf (a) in storage dish and (b) applied to a foot ulcer 76
Other acellular products such as Biobrane®, Integra®, OASIS®, and PriMatrixT  have the
benefit of long shelf lives of two or more years.78',79,80,81 Biobrane®, which can also be
considered a biomaterial dressing, is comprised of collagen-bound nylon partially embedded in a
silicone film.78 Integra® Dermal Regeneration Template is a bilayer skin substitute which
consists of a porous collagen and chrondroitin-6-sulfate matrix with a layer of silicone. It has
FDA approval for the treatment of burns and for reconstructive surgery. 79 OASIS® Wound
Matrix is fabricated from acellular, porcine intestinal submucosa and can be used to treat partial
and full thickness wounds.80 Lastly, PriMatrixTM is an acellular dermal repair scaffold produced
(a,
from fetal bovine skin. It is indicated for use on wounds including partial and full thickness
wounds, ulcers, and second degree burns.81
The other segment of the interactive wound care market is biomaterial-based products.
While skin substitutes currently draw in greater revenues, biomaterials are expected to draw in
revenues equal to those of skin substitutes by 2013. The majority of biomaterial dressings rely
on the wound healing benefits of collagen or hyaluronic acid. Commercially available products
include Medifil®, SkinTemp , B.G.C Matrix®, Fibracol®, Nu-Gel®, hyCURE®, HYCOAT®, and
Hyalofill®.65
4.3.3 Other Commercialized Technologies
Moist or occlusive dressings make up the majority of revenues from the advanced wound
care market (Figure 13). As their name implies, these dressings are designed to promote moist
wound environments which in turn increase the rate of reepithelialization.8 2 Types of moist
wound dressings include hydrogel, hydrocolloid, alginate, foam, and transparent film dressings.
Concerns over increased antibiotic resistance and difficulty in identifying infected wounds have
also led to the growth of an antimicrobial dressings market. While the majority of the products
are based on silver, several products based on iodine have also been developed.64
Many products which combine the functions of biomaterial, moist, and antimicrobial
dressings are now being commerialized. Examples of newer, innovative products include
Insense's Oxyzyme and Iodozyme. These products consist of two hydrogel dressings containing
glucose, salts, and moisturizers. The dressings also contain a biochemical system designed to
enhance wound healing by oxygenating the wound. The antimicrobial activity of the dressings is
due to the release of iodine. Ethicon's Promogran PRISMATM Matrix is another fairly new
product; this occlusive dressing combines collagen, oxidized regenerated cellulose, and silver.83
Organogenesis has also developed a collagen-based antimicrobial dressing, FortaDermTM, which
is to be made commercially available sometime this year.84
Other emerging and competing technologies that must be considered in entering this
market include growth factor-based products such as Regranex, negative pressure wound therapy
(NPWT), hyperbaric wound therapy, and LED technology for wound healing.64 NPWT in
particular has shown much promise. This treatment consists of a foam dressing secured with an
occlusive transparent film; a drainage tube is inserted into the dressing and connected to a
vacuum source to apply localized subatmospheric pressure to the wound bed. Wound exudate is
removed by the vacuum and collected in a canister. Kinetic Concepts Inc., the developers of the
V.A.C.® Therapy System, have also developed silver dressings to be used in conjunction with the
V.A.C.® Bluesky Medical has also developed a wound treatment system based on NPWT.83
4.3.4 Technologies in Development
All of the products currently available commercially, with the exception of grafts, do not
address the issue of microvascularization. There are, however, other groups currently
researching methods of accomplishing this. Xu et al. have developed a poly(L-lactide-co-s-
caprolactone) (75:25) nanofibrous scaffold with an aligned structure. When seeded on the
scaffold, SMCs exhibit oriented attachment and migration along the nanofibers. 85 Stephan et al.
have developed another composite scaffold composed of a luminal polycaprolactone (PCL) layer
and medial porous polyurethane (PU) layer. These scaffolds have been coated with various
adhesion fragments from vascular elastic fibers to enhance and regulate cell attachment and
function. 86 Peters et al. have taken yet another approach by incorporating VEGF into porous
PLGA matrices for localized, sustained delivery of the growth factor. When transplanted into
severe combined immunodeficient (SCID) mice, an increase in capillary density was observed
with and without additional HMVECs.87
Some research is also now being conducted to vascularize tissue-engineered skin
specifically. By seeding HUVECs on chitosan / collagen biopolymers with dermal fibroblasts
alone or also with keratinocytes, researchers at Laval University in Quebec have constructed
matrices containing capillary like structures (CLS).4 5 When these skin equivalents were
implanted in mice, CLS were shown to contain red blood cells within four days, thus suggesting
the inosculation of the capillaries with the vascular systems of the host mice. Controls did not
contain blood until 14 days after grafting.88 Other studies by Nor et al. have shown murine
blood cells in human microvessels seven days after transplanting HDMEC-seeded PLLA
sponges into SCID mice. Additionally, non-functional CLS decreased significantly after seven
days and essentially disappeared after twenty-one days. 89
While these groups have been able to form CLS in vitro, the structures are not connected
into any type of network. This must be done by the body after implantation into a host. As a
result, while these CLS may speed up the process of vascularizing regenerated tissue, they may
not necessarily ensure the early survival of cells that have been seeded in the matrices. Draper's
technology has the advantage of providing a complete microvascular network which can deliver
nutrients and oxygen to cells immediately after implantation.
4.4 Draper's Potential Product
A schematic of a potential wound healing product based on Draper's technology is shown
in Figure 16. The product would consist of a porous, biodegradable polymer scaffold with an
embedded multilayer network of channels. After proper wound debridement and preparation, the
scaffold would be placed in the wound bed and secured with additional dressings. A variety of
sizes of scaffolds would be manufactured to treat wounds of varying sizes. Additionally,
scaffold regions could be trimmed or compressed slightly to conform to wound geometries.
Medical grade tubing would be attached to the inlet and outlet of the network of channels within
the scaffold, and medium would be perfused through the network using an external pump. This
medium would consist of three main components: a base nutrient medium to nourish host cells as
they infiltrated the scaffold, an assortment of growth factors to promote angiogenesis and
fibroblast migration and proliferation, and silver nanoparticles to aid in fighting off infections.
Additionally, the channels and scaffold could be functionalized with adhesion promoting
peptides to further promote cellular infiltration. The scaffold would slowly degrade and be
replaced as cells migrated in and began to synthesize their own matrix.
Figure 16. Schematic of potential wound healing product based on Draper's technology
An acellular product has been suggested to limit the cost and complexity of
manufacturing. Unlike cell-based skin substitutes which depend on the cells to provide growth
factors, Draper's product will exogenously supply growth factors through the perfusion medium.
The scaffold will focus on enhancing wound healing by promoting the migration of cell
populations into the scaffold and by promoting angiogenesis to sustain these populations. The
inherent microvascular network will allow migration of cells and sustain viability immediately
after application by temporarily supplying the cells with nutrients throughout the thickness of the
scaffold even prior to angiogenesis. This may provide a better solution as a significant number
of blood vessels formed during wound healing eventually disappear.
4.5 Intellectual Property
Draper currently has four U.S. patent applications being processed (Table 6).90,91,92,93
The most recent application claims a method for designing and fabricating three dimensional
physiologically based fluidic networks similar to the one previously described. However, the
model differs in being based on flow rates in the channels instead of shear stress, a model used
earlier at Draper." While the assignment of these patents is split between Draper and
Massachusetts General Hospital, also referred to as the General Hospital Corporation, due to
collaboration during research efforts, Draper will be able to license these patents as necessary,
giving Draper a strong claim to the fabrication methods used in producing the microvascular
networks. Patents on fundamental microfabrication technologies used by Draper have already
expired, and patents on more recent advances, such as HARMs, do not address biotechnology
applications. A brief patent search has revealed that the majority of patents related to
microfluidic devices focus on medical and chemical diagnostic applications. While a few patents
were found for wound dressings with microchannels or conduits, these patents included
additional features such as high aspect ratio channels, fluid reservoirs, nebulizers, and backing
layers which are lacking in Draper's microvascular networks.
Table 6. List of Draper's current patent applications9' 91 92' 93
U.S. Patent Application Patent Title
20020182241 Tissue engineering of 3d vascularized [sic] using microfabricated polymer assembly technology
20030003575 Fabrication of vascularized tissue using microfabricated 2d molds
20050202557 Micromachined bilayer unit of engineered tissue
20060136182 3d construct for the design and fabrication of physiological fluidic networks
With regards to biomaterials, many commercially available options exist which are public
domain. While it would be preferable to avoid licensing these technologies, it is possible that
further studies will suggest patented options as being most compatible with Draper's technology
and intended applications. For example, PGS, used in recent studies, is currently in the process
of being patented under a broader patent covering biodegradable polymers formed via
condensation polymerization of glycerol and a diacid.26,94
In applying this technology towards wound healing, additional patents may be needed
which specify methods tailored more towards the application. At this point, there is no concern
of infringing on patents for existing skin substitutes due to the fact that these patents all involve
the use of collagen, dermal fibroblasts, and/or epidermal keratinocytes.
4.6 Business Plan
4.6.1 Cost Analysis
A simplified cost model was developed for the production of an interactive wound
dressing based on Draper's technology. Assuming a market of 7 million individuals and a
production volume based on capturing half a percent of the market, the estimated cost of
producing Draper's wound dressing is $65 per dressing. In the model (Table 7), material and
equipment costs were based on the processing requirements for a PLGA microvascular network
5 cm in diameter. Ten layers of microvascular networks would be stacked 200 gm apart to give
a final thickness of approximately 3 mm. Due to the relatively small number of silicon molds
required, it was decided that these molds would not be produced in-house but instead by an
outside contractor. The calculation of material costs for the perfusion media was based on a one
month supply of media perfused at a rate of 100 ptL/hr. The formulation of the perfusion media
was based on the previously stated concentrations of growth factors, 0.5 ppm of silver
nanoparticles, and a base medium with nutrient concentrations similar to Dulbecco's Modified
Eagle's Medium. The cost of manufacturing perfusion pumps was not included in the model for
reasons which will be addressed later.
Table 7. Summary of cost model
Variable Costs
Material Cost
Energy Cost
Labor Cost
Total Variable Cost
Fixed Costs
Main Machine & Tooling Cost
Auxiliary Equipment Cost
Fixed Overhead Cost
Building Cost
Maintenance Cost
Total Fixed Cost
Total Fabrication Cost
Per piece
$51.00
$0.54
$9.47
$61.01
Per piece
$0.77
$0.14
$0.85
$1.94
$0.14
$3.85
$64.86
Per year
$1,045,500
$11,093
$194,138
$1,250,730
Per year
$15,763
$2,866
$17,523
$39,780
$2,920
$78,852
$1,329,582
Percent
78.63%
0.83%
14.60%
94.07%
Percent
1.19%
0.22%
1.32%
2.99%
0.22%
5.93%
100.00%
Investment
$134,200
$24,400
$375,000
$509,200
4.6.2 Business Model
Here, the model of a manufacturing or product company has been chosen for the
marketing of Draper's technology. Materials would be purchased from distributors, and the
company would produce the primary products involved in the wound healing application - the
porous, vascularized scaffolds and the necessary perfusion medium. A partnership would be
1
formed with an existing biomedical equipment company to produce and sell the pumps necessary
for the perfusion of media through the scaffolds. This would give the partner company an
additional product to sell without significant research efforts on their end.
Figure 17 shows the value added for each group involved from production to use of the
scaffolds. Assuming the product is sold at ten times the cost, the patient will pay approximately
$650 for the wound dressing and a one-month supply of perfusion media. Depending on the
duration for which perfusion media is necessary, this could be more cost effective than other skin
substitutes currently on the market. On average, de-cellularized allografts only cost $300 per
sheet, but more complex skin substitutes cost between $900-1,300.65 If professionals' fees are
included, a single application of Apligraf costs almost $1500. Furthermore, several applications
of skin substitutes are typically made before healing is complete. However, even with multiple
applications, treatment with skin substitutes has still been shown to be more cost effective than
traditional treatments for non-healing ulcers. The annual cost of treatment with Apligraf is
estimated at approximately $20,000 while traditional treatment can cost nearly $28,000. 95
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Figure 17. Value added at each level for Draper's wound dressing
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Because the value for the consumer and final cost-benefit analysis depend on how
quickly ulcers can be healed, the efficacy of Draper's product must be proven for this application
to be successful. To accomplish this, animal and human clinical trials will be necessary.
Clinical trials and completion of FDA regulatory procedures will be costly with regards to both
time and money, but they are necessary for any tissue engineering application pursued with
Draper's technology.
4.6.3 FDA Regulatory Procedures
Many steps will be involved in obtaining FDA approval for Draper's wound healing
product. As the product consists of both a biological product and a device, it must be approved
as a combination product. The determination of which FDA center is responsible for its
clearance will depend on what its primary mode of action is. The type of combination product
will also determine whether or not more than one marketing application is needed or desired.
Approval of a new biological product typically requires a biologics license application (BLA).96
A class III "significant risk" device, which is the classification of most skin substitutes, requires
a premarket approval application (PMA). The application for PMA includes the following: all
known safety and efficacy reports, a description of device components and principle(s) of
operation, a description of manufacturing processes and controls, a reference to any applicable
standards under Section 514 of the Federal Food, Drug, and Cosmetic Act, and samples of the
device, its components, and its proposed labeling.64 Each application has its associated fees
ranging from approximately $240,000 to $670,000; however, fee waivers and reductions may be
available under certain circumstances. 96
To collect clinical data for the PMA application, an investigational device exemption
(IDE) for the product must first be approved; after obtaining approval, clinical trials must be
conducted and passed.64 Clinical trials for other advanced wound care products have consisted
of approximately twenty individuals in phase I trials, forty in pilot (phase II) trials, and 200 in
pivotal (phase III) trials.66,83,97 Based on estimates of Ortec's OrCel clinical trials on burn and
EB patients, the cost of each human clinical trial can be expected to be around $8,000; this does
not include indirect expenses such as additional salaries, rent, and overhead. 98
5 Conclusion
A novel technology has been presented here for the in vitro engineering of microvascular
networks through the use of microfabrication techniques. This technology is still very much in
the early stages of development and thus has several significant challenges which must be
overcome prior to marketing. While the ultimate goal is the regeneration of complex organs,
nearer term applications may exist for this technology. Thus, an initial assessment has been
made as to the feasibility of applying this technology towards the treatment of chronic wounds.
While the advanced wound management market is substantial and growing, it is also highly
competitive and thus a fairly difficult and high risk market to enter. By focusing on angiogenesis
and supplying a complete microvascular network from the time of application, Draper's
technology offers an innovative approach to the healing of chronic wounds. However, the
greater efficacy of this approach as compared to the approaches of other advanced wound
dressings must be proved for the technology to succeed in this application. Other factors such as
cost, ease of use, and acceptance by insurance companies, hospitals, and patients, will also need
to be considered. As Draper continues to develop its technology, research into other potential
near term applications should be continued. Closer collaboration with clinical researchers and
doctors will also be desirable in future stages of development in order to improve chances of
successful passage through FDA regulatory processes and clinical trials once these are necessary.
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